IL-12 enhances efficacy and shortens enrichment time in cytokine-induced killer cell immunotherapy

@article{Helms2010IL12EE,
  title={IL-12 enhances efficacy and shortens enrichment time in cytokine-induced killer cell immunotherapy},
  author={Mike W. Helms and Jennifer A Prescher and Yu-an Cao and Steven A. Schaffert and Christopher H. Contag},
  journal={Cancer Immunology, Immunotherapy},
  year={2010},
  volume={59},
  pages={1325-1334}
}
Cytokine-induced killer (CIK) cells are T cell derived ex vivo expanded cells with both NK and T cell properties. They exhibit potent anti-tumor efficacy against various malignancies in preclinical models and have proven safe and effective in clinical studies. We combined CIK cell adoptive immunotherapy with IL-12 cytokine immunotherapy in an immunocompetent preclinical breast cancer model. Combining CIK cells with IL-12 increased anti-tumor efficacy in vivo compared to either therapy alone… CONTINUE READING

From This Paper

Figures, tables, and topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 28 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 46 references

A (2007) Interleukin-12: biological prop- erties and clinical application

M Del Vecchio, E Bajetta, +4 authors Anichini
Clin Cancer Res • 2007
View 1 Excerpt

Interleukin-12: biological properties and clinical application.

Clinical cancer research : an official journal of the American Association for Cancer Research • 2007

Similar Papers

Loading similar papers…